Curtis Jamison Perry, MD, PhD
Instructor of Medicine (Medical Oncology & Hematology)About
Research
Publications
2025
Precancer exercise capacity and metabolism during tumor development coordinate the skeletal muscle–tumor metabolic competition
Leitner B, Fosam A, Lee W, Zilinger K, Nakandakari S, Zhang X, Gaspar R, Zhu W, Perry C, Rabinowitz J, Perry R. Precancer exercise capacity and metabolism during tumor development coordinate the skeletal muscle–tumor metabolic competition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2508707122. PMID: 41325517, PMCID: PMC12704748, DOI: 10.1073/pnas.2508707122.Peer-Reviewed Original ResearchInteractions among tumor subtype, PPARγ expression, and adipose proliferation shape outcomes in breast cancer
Shah A, Liu K, Liu R, Ramshankar G, Perry C, Perry R. Interactions among tumor subtype, PPARγ expression, and adipose proliferation shape outcomes in breast cancer. Physiological Reports 2025, 13: e70649. PMID: 41236441, PMCID: PMC12617248, DOI: 10.14814/phy2.70649.Peer-Reviewed Original ResearchMolecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma
Vaidya P, Wu S, Bryant D, Perry C, Prakash V, Lou E, Guo T, Brownell I, Darabi S, Gao L, Abdulla F, Park S. Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma. Cancers 2025, 17: 3508. PMID: 41228301, PMCID: PMC12609552, DOI: 10.3390/cancers17213508.Peer-Reviewed Original ResearchTargeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma
Frey A, Clulo K, Fei Y, Dumit T, Scallo F, Allen J, Chang E, Perry C, Wirth L, Jacobs D, Braun D, Bosenberg M, Tran T, Clune J, Kluger H, Olino K, Ishizuka J. Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma. Cell Reports 2025, 44: 116359. PMID: 41042672, PMCID: PMC12646823, DOI: 10.1016/j.celrep.2025.116359.Peer-Reviewed Original ResearchThis study investigates an IL-7-enhanced mRNA vaccine targeting virus-associated Merkel cell carcinoma, showing durable immune responses in mouse models and patient samples, addressing cancer recurrence challenges.
2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors
Kahn A, Perry C, Etts K, Kluger H, Sznol M. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The Oncologist 2023, 29: e507-e513. PMID: 37971411, PMCID: PMC10994263, DOI: 10.1093/oncolo/oyad300.Peer-Reviewed Original ResearchCausal identification of single-cell experimental perturbation effects with CINEMA-OT
Dong M, Wang B, Wei J, de O. Fonseca A, Perry C, Frey A, Ouerghi F, Foxman E, Ishizuka J, Dhodapkar R, van Dijk D. Causal identification of single-cell experimental perturbation effects with CINEMA-OT. Nature Methods 2023, 20: 1769-1779. PMID: 37919419, PMCID: PMC10630139, DOI: 10.1038/s41592-023-02040-5.Peer-Reviewed Original Research
2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.Peer-Reviewed Original Research
2019
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. Journal For ImmunoTherapy Of Cancer 2019, 7: 172. PMID: 31291990, PMCID: PMC6617639, DOI: 10.1186/s40425-019-0643-8.Peer-Reviewed Original ResearchB cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.Peer-Reviewed Original Research
2018
Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer
Wang Y, Nasiri AR, Damsky WE, Perry CJ, Zhang XM, Rabin-Court A, Pollak MN, Shulman GI, Perry RJ. Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. Cell Reports 2018, 24: 47-55. PMID: 29972790, PMCID: PMC6056247, DOI: 10.1016/j.celrep.2018.06.008.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Curtis Jamison Perry, MD, PhD, is a medical oncologist who specializes in treating genitourinary cancers. He focuses on diagnosing and managing cancers of the bladder, prostate, and testicles.
Dr. Perry’s research explores the immune system’s role in cancer. His work includes using advanced single-cell techniques and AI tools to study immune responses in cancer patients. His goal is to improve treatment options for all patients by deepening our understanding of cancer immunology and enhancing cancer care for patients whose tumors develop resistance to immunotherapies. He is dedicated to partnering with patients throughout their cancer care.
Dr. Perry earned his medical and doctoral degrees from Yale School of Medicine, as well as his residency in internal medicine and a fellowship in hematology/oncology. He is an instructor of medicine at Yale School of Medicine.
Clinical Specialties
Genitourinary Oncology; Medical Oncology; Urologic Oncology
News & Links
News
- March 23, 2026
Yale Launches Innovative Clinical Trial for Metastatic Bladder Cancer
- January 12, 2026
How Exercise Slows Tumor Growth
- October 28, 2025
Yale Develops Dual-Action Vaccine to Combat Aggressive Merkel Cell Carcinoma
- June 06, 2025
Yale Cancer Center Researchers and Trainees Present at 2025 ASCO Annual Meeting
Get In Touch
Contacts
Appointment Number
Locations
CMCO
Lab
300 George Street, Fl 6
New Haven, CT 06511
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.